Testing semaglutide for weight loss in people with advanced lung disease
Tests whether semaglutide is tolerable in adults with advanced lung disease and obesity.
Key facts
- Who runs it
- University of Pennsylvania
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Registry title
- Feasibility of Semaglutide in Advanced Lung Disease
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 8 people, planned
- Started
- 29 Jan 2024
- Expected to end
- 28 Dec 2027
- Type of study
- Interventional
- Treatments tested
- Semaglutide Pen Injector
- Record updated
- 21 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity and advanced lung disease who need extra oxygen when active. It tests whether semaglutide can be taken and tolerated for 12 weeks.
- Age
- Over 18 and up to 80 years.
- Sex
- All sexes can join.
- Disease stage
- Advanced lung disease: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension. Needs extra oxygen on exertion. BMI over 30 kg/m2.
- Earlier treatment
- Stable treatment for 90 days and use of disease-modifying therapy. No weight loss medication in the last 90 days.
Main reasons for not taking part
- Diabetes
- Pregnant or breastfeeding
- Recent weight loss
- Recent or chronic stomach and gut problems, or gastroparesis
- History or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension
- Age > 18
- BMI > 30 kg/m2
- Requires supplemental oxygen on exertion
- Stable treatment regimen X 90 days
- Use of disease-modifying therapy
Who cannot take part
- Use of weight loss medication in last 90 days
- Prior suicide attempt
- Diabetes
- History of gastroparesis
- History of scleroderma
- Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)
- Uncontrolled thyroid disease
- History of acute/chronic pancreatitis
- Pregnant or Breastfeeding
- Recent weight loss
- Recent or chronic GI complaints
- Hospitalized at time of evaluation
- Suicidal ideation in last 90 days
- Presence of a pacemaker or defibrillator
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- University of Pennsylvania Perelman School of MedicinePhiladelphia, United StatesContact: Apurva RajeTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease.
Read full original descriptionShow less
The main question[s] it aims to answer are:
1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight?
Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.
The group in the trial
- Study Drug (semaglutide)Treatment being tested
Semaglutide Pen Injector 1.0 mg weekly Once weekly subcutaneous injection Other Name: Wegovy
Treatment: Semaglutide Pen Injector
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Feasibility of Semaglutide Therapy for Weight Loss in Advanced Lung Disease: A Pilot Study
- Plain-language title
- Testing semaglutide for weight loss in people with advanced lung diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05746039, who can take part
- Record updated
- 21 April 2026